The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Contact form on their website via the contact us page.
I have just sent them a message requesting an update. Might be useful if others did the same.
Half way through January and RM hasn't engaged with his shareholders.
Via the 2022 AGM it was confirmed by the CEO that Synairgen would be in a trial before end of Winter 22 / 23. Target date missed.
The CEO has reported trials to start in H1 so that could also see us missing another winter.
Rough seas continue.
Reasoned debate? I am not bothered about what other companies are doing with JVs.
Happy to discuss what Synairgen are doing. We last had an update 3 months ago about P2 trials starting subject to preparation and regulatory approval timelines, trials anticipated to start in H1 2024.
'subject to'
'anticipated'
Marsden should be a politician. never a straight answer!
RM could update us and say 'everything is done at our end and we are now awaiting regulatory approval' Is that too simple or do we think they are struggling at their end.
We have no idea.
Dunk - There you have what? I invested in this company to bring a product to market not pay overheads.
For the last two years, overheads have been paid to establish what? We still have no confirmed trials or recovery plan.
Some on here think this company is near to a JV / acquisition. £12M for an excel spreadsheet of 'data'?
Look at the history of this company, 20+ years of interferon 'research'. Never been a greater need for anti viral treatment and they are trading at an all time low. They couldn't even attract a JV / acquisition on the last set of P2 results during a pandemic.
SNG001 not used in a trial since Nov 2021. CEO won't communicate with his shareholders and hasn't apologised once for this big mess.
97% down since P3 failure. How this company continues to get away with treating shareholders like this I have no idea.
CEO Dick Marsden on £300K a year. We will hear from him when he needs more funds, you can guarantee that.
Any sign of a rise and I will sell up. No confidence in the board to deliver anything.
Directors buys at 5p? No, they sold some share at a high of c. £2.00... Says everything.
Talks of JV and acquisition is nonsense.
When I called the 'office landline' last year they were operating from a mobile telephone and didn't have the ability to transfer calls.
The CEO provides updates only to conform with his professional obligations to the market.
The goal posts for the proposed P2 trials have already been moved 3 times.
SNG001 not used in any trials since Nov 2001.
Various approaches to 'relaunch' SNG001 with conferences, pod casts and Scientific American have not resulted in any increase of SP.
New director appointments have been very quiet and Stephen Holgate no longer pops up.
Based on the information provided to shareholders, we are miles away from commercials.
SHAMBLES.
I just can't see anything positive coming from this company and absolutely no point in selling a 5p.
Sir Stephen Holgate has been very quiet since his interview prior to P3 failure in America, Nov / Dec 2021 if I recall correctly. Don't hear him banging the drum for this drug anymore. Professional embarrassment perhaps?
Any word from Dr Felicity ('Flic') Gabbay since she joined us or just another one taking a monthly wage?
Tommy - The company has had 20+ years to launch a product.
How much more time do they need?
Easy to spend other peoples money.
Awful communications.
AGM = Smile, nod in the right places and get the shareholders out the door with as little fuss as possible.
If you attended the AGM or did not the AGM, I believe the SP is still 5-6p and still no confirmed trial start date?
SNG001 not used in any trials since 2021.
RM has received in excess of £600K+ salary since then. For what progress?
Tommy - What are Synairgen actually doing on a day to day basis? No one has a clue. Why? Because the board don't even know what the exact plan is either.
H1 for planned trials will soon become 'by end of 2024'.
We have absolutely no idea what is happening here.
We have no products. no solid plan moving forwards and is always 'subject to' and communications from the company could not be any worse. What is the purpose to the company? It just pays overheads.
RM should not be in this role. Takes £85M plus previous fund raises. Always front and centre when he needs something and no where to be seen during the tough time.